자폐스펙트럼장애 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Autism Spectrum Disorder Treatment Market Summary

The global autism spectrum disorder treatment market size was valued at USD 2.71 billion in 2025 and is projected to grow from USD 2.87 billion in 2026 to USD 4.40 billion by 2033, at a CAGR of 6.3% from 2026 to 2033. North America held the largest share of 51.8% of the global market in 2025. The industry is witnessing substantial growth due to the increasing prevalence of autism spectrum disorder and rising awareness regarding the importance of early diagnosis and intervention.

Healthcare providers, educational institutions, and government organizations are increasingly focusing on strengthening developmental healthcare programs to improve access to autism-related therapies and supportive care services. The market primarily consists of behavioral therapy, speech therapy, occupational therapy, social skills training, and medications used to manage associated symptoms, including irritability, anxiety, aggression, and hyperactivity. Growing emphasis on multidisciplinary treatment approaches is further supporting market expansion, as autism spectrum disorder often requires long-term therapeutic, educational, and behavioral support. In addition, increasing availability of specialized autism care centers and rehabilitation programs is improving treatment accessibility across multiple healthcare settings. Rising public awareness initiatives and supportive healthcare policies are also contributing to higher diagnosis rates and increasing demand for autism spectrum disorder treatment services globally.

As awareness and diagnosis rates continue to increase, the market is also experiencing significant advancements in therapeutic technologies and neurodevelopmental research aimed at improving long-term patient outcomes and quality of life. Pharmaceutical and biotechnology companies are focusing on the development of targeted therapies designed to address behavioral and neurological symptoms associated with autism spectrum disorder. Simultaneously, digital healthcare solutions such as teletherapy platforms, AI-enabled behavioral monitoring systems, assistive communication devices, and virtual intervention programs are gaining broader adoption within the treatment landscape. These technological advancements are helping improve treatment accessibility and continuity of care, particularly in underserved regions where access to specialized therapists remains limited. In addition, growing collaboration between research institutions, healthcare providers, and autism advocacy organizations is accelerating innovation in developmental disorder management. Increasing investment in pediatric neurological care and personalized treatment models is further strengthening the overall growth potential of the market.

Additionally, the industry is also driven by these ongoing technological and therapeutic advancements. The market is shifting toward more individualized and integrated models of patient care. Healthcare providers are placing greater emphasis on customized treatment plans that combine behavioral therapy, speech therapy, occupational therapy, educational intervention, and pharmacological management based on individual patient needs and symptom severity. This evolving treatment approach is improving long-term developmental support and enhancing overall patient engagement across different age groups. Moreover, continuous advancements in digital behavioral assessment tools, remote monitoring technologies, and virtual care platforms are transforming the delivery of autism-related healthcare services. The market is also benefiting from expanding collaboration between pharmaceutical companies, therapy providers, academic institutions, and support organizations focused on improving developmental disorder management strategies. Furthermore, increasing investment in early intervention programs and supportive care infrastructure is expected to continue driving innovation and sustained growth within the market.

Global Autism Spectrum Disorder Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global autism spectrum disorder treatment market report based on type, application, distribution channel, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Antipsychotic Drugs
• Selective Serotonin Reuptake Inhibitors
• Stimulants
• Sleep Medications
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Autistic Disorder
• Asperger Syndrome
• Pervasive Developmental Disorder
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Autism Spectrum Disorder Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Autism Spectrum Disorder Treatment Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Stimulants
  • 4.4.1. Stimulants Market, 2021 - 2033 (USD Million)
• 4.5. Antipsychotic Drugs
  • 4.5.1. Antipsychotic Drugs Market, 2021 - 2033 (USD Million)
• 4.6. Selective Serotonin Reuptake Inhibitors
  • 4.6.1. Selective Serotonin Reuptake Inhibitors Market, 2021 - 2033 (USD Million)
• 4.7. Sleep Medications
  • 4.7.1. Sleep Medications Market, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Autism Spectrum Disorder Treatment Market: Application Business Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Autistic Disorder
  • 5.4.1. Autistic Disorder Market, 2021 - 2033 (USD Million)
• 5.5. Asperger Syndrome
  • 5.5.1. Asperger Syndrome Market, 2021 - 2033 (USD Million)
• 5.6. Pervasive Developmental Disorder
  • 5.6.1. Pervasive Developmental Disorder Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Autism Spectrum Disorder Treatment Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2025 & 2033
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Autism Spectrum Disorder Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 7.4. North America
  • 7.4.1. North America Autism Spectrum Disorder Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Autism Spectrum Disorder Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Curemark LLC
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Bristol-Myers Squibb Company
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Merck & Co., Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Novartis AG
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Eli Lilly and Company
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Pfizer Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Johnson & Johnson Services Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Otsuka Pharmaceutical Co., Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Yamo Pharmaceuticals
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. F.Hoffmann-La Roche Ltd.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Axial Therapeutics Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives